First-Line Treatment for Menopausal Hot Flashes

Primary Nonhormonal First-Line Options

The National Comprehensive Cancer Network recommends nonhormonal pharmacologic therapy as first-line treatment for menopausal women with hot flashes, with gabapentin 900 mg/day at bedtime or venlafaxine 37.5-75 mg daily being the preferred initial options 1, 2
Gabapentin reduces hot flash severity by 46% compared to 15% with placebo, with efficacy equivalent to estrogen, in menopausal women with hot flashes 2, 3
Venlafaxine reduces hot flash scores by 37-61% compared to 27% with placebo, with onset of action within 1 week, in menopausal women with hot flashes 2, 3

Hormonal therapy is the most effective treatment, reducing hot flashes by approximately 75% compared to placebo, but should only be used after nonhormonal options have failed or are not tolerated, in menopausal women with hot flashes 2
The National Comprehensive Cancer Network recommends transdermal estrogen formulations over oral due to lower rates of venous thromboembolism and stroke, in menopausal women with hot flashes 4, 2

The National Comprehensive Cancer Network recommends avoiding hormonal therapy in women with a history of hormonally mediated cancers, abnormal vaginal bleeding, active or recent history of thromboembolic events, pregnancy, or active liver disease 1, 2, 4

The treatment algorithm recommends starting with gabapentin 900 mg/day at bedtime or venlafaxine 37.5-75 mg daily, and reviewing efficacy at 2-4 weeks for SSRIs/SNRIs and 4-6 weeks for gabapentin, in menopausal women with hot flashes 2, 3

The National Comprehensive Cancer Network recommends never using paroxetine or fluoxetine in women taking tamoxifen due to CYP2D6 inhibition, and always tapering SSRIs/SNRIs gradually when discontinuing to minimize withdrawal symptoms, in menopausal women with hot flashes 1, 2, 3

Venlafaxine at 75 mg/day reduces hot flash scores by 61% compared to 27% with placebo, with dose-dependent efficacy starting at 37.5 mg/day and maximizing at 75-150 mg/day, according to the Annals of Oncology 5
The National Comprehensive Cancer Network recommends paroxetine 7.5 mg as an alternative first-line option that significantly reduces both frequency and severity of vasomotor symptoms 6
Paroxetine 7.5 mg daily reduces hot flash composite scores by 62-65% in controlled trials, as reported in the Annals of Oncology 5
Critical caveat: Paroxetine must be avoided in women taking tamoxifen due to strong CYP2D6 inhibition that blocks tamoxifen conversion to active metabolites, as noted by the National Comprehensive Cancer Network 6
Fluoxetine shows the weakest and most inconsistent efficacy, with only 50% reduction in hot flash scores versus 36% for placebo, according to the Annals of Oncology 5
Long-term efficacy of fluoxetine is not demonstrated—at 9 months, fluoxetine was no better than placebo, as reported in the Annals of Oncology 5
Both venlafaxine and paroxetine require gradual tapering to prevent withdrawal symptoms due to their short half-lives, as recommended by the Annals of Oncology and the National Comprehensive Cancer Network 5, 6
Gabapentin 900 mg/day at bedtime reduces hot flash severity by 46% and may be particularly useful for women with sleep disturbance, according to the National Comprehensive Cancer Network 6

The National Comprehensive Cancer Network (NCCN) explicitly recommends against coadministration of paroxetine or fluoxetine with tamoxifen due to dangerous drug interactions that reduce tamoxifen efficacy 7, 8
The NCCN states that paroxetine and fluoxetine should not be used in women taking tamoxifen, as they potently inhibit CYP2D6, blocking the conversion of tamoxifen to its active metabolites, which may significantly reduce tamoxifen's anti-cancer efficacy 7, 8

For women with breast cancer history, venlafaxine 37.5-75 mg daily is a preferred first-line nonhormonal treatment, with minimal CYP2D6 interaction, making it safe for tamoxifen users 7
For women with cardiovascular disease history, nonhormonal options (venlafaxine, gabapentin, SSRIs) are preferred over hormonal therapy, with monitoring of cardiovascular status as indicated 9

The American College of Cardiology and other guideline societies recommend careful evaluation of treatment efficacy and safety, including monitoring for potential drug interactions and cardiovascular risks 9
Gradual tapering of SSRIs/SNRIs is essential to prevent withdrawal symptoms, and verification of tamoxifen use is crucial before prescribing any SSRI 7, 8